Table 1.
PRIME model parameters and data sources
| parameter | value | source |
|---|---|---|
| Birth cohort size (female) | Additional file | CPSY |
| Cohort size at vaccination age (female) | Additional file | CPSY |
| Target age group | 9/16 | [20] |
| Vaccine efficacy vs HPV 16/18 | 100% | [23, 24] |
| Vaccine efficacy vs HPV 16/18/31/33/45/52/58 | 100% | [23, 24] |
| Coverage (all doses) | 80% | [26, 25] |
| Vaccine price per FIG | Additional file | CPP |
| Vaccine delivery cost per FIG | Additional file | CPP |
| Total vaccine cost per FIG | Additional file | CPP |
| Cancer treatment cost (per episode, over lifetime) | US$7547 | [22] |
| DALYs for cancer diagnosis | 0.08 | [21] |
| DALYs for non-terminal cancer sequelae (per year) | 0.11 | [21] |
| DALYs for terminal cancer | 0.78 | [21] |
| Discount rate | 3% | [16] |
| Proportion of cervical cancer cases that are due to HPV 16/18 | 69.1% | [21] |
| Proportion of cervical cancer cases that are due to HPV 16/18/31/33/45/52/58 | 92% | [21] |
| Discounted GDP per capita | Additional file | CPSY |
CPSY 20 China and Provincial Statistics Yearbook, CPP Centralized procurement platform